{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-22-000029","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2022-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.474372+00:00","generated_at":"2026-06-27T05:49:11.779512+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Exelixis files new patent infringement suit against MSN over generic CABOMETYX","bullets":["Filed complaint in Delaware asserting infringement of three new patents (11,091,439; 11,091,440; 11,098,015) related to cabozantinib.","MSN amended its ANDA for generic CABOMETYX tablets (20/40/60 mg); Exelixis seeks injunction and approval date no earlier than patent expiration (latest Jan 15, 2030).","This new case is separate from the 2019/2020 MSN ANDA Actions, which are scheduled for trial in May 2022.","Exelixis also seeks order that FDA approval of MSN's ANDA be delayed until after patent expirations."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-22-000029","json":"https://secwatch.observer/filing/0000939767-22-000029.json","markdown":"https://secwatch.observer/filing/0000939767-22-000029.md","text":"https://secwatch.observer/filing/0000939767-22-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000029/0000939767-22-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000029/exel-20220223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:49:11.779512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}